Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cell Impact's Enterprise Value is €5.45 Mil.
Cell Impact's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €-11.34 Mil. Therefore, Cell Impact's EV-to-EBIT ratio for today is -0.48.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Cell Impact's Enterprise Value is €5.45 Mil.
Cell Impact's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-4.66 Mil. Therefore, Cell Impact's EV-to-EBITDA ratio for today is -1.17.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Cell Impact's Enterprise Value is €5.45 Mil.
Cell Impact's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €0.53 Mil. Therefore, Cell Impact's EV-to-Revenue ratio for today is 10.23.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Cell Impact's Enterprise Value is €5.45 Mil.
Cell Impact's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-4.18 Mil. Therefore, Cell Impact's EV-to-FCF ratio for today is -1.30.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Cell Impact (FRA:ICL) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Cell Impact's current Enterprise Value is €5.45 Mil.
Cell Impact's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-11.34 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Cell Impact's current Enterprise Value is €5.45 Mil.
Cell Impact's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.66 Mil.
Cell Impact's current Enterprise Value is €5.45 Mil.
Cell Impact's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.53 Mil.
Cell Impact's current Enterprise Value is €5.45 Mil.
Cell Impact's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.05 Mil.
Cell Impact's current Enterprise Value is €5.45 Mil.
Cell Impact's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cell Impact Enterprise Value Related Terms
Cell Impact Enterprise Value Historical Data
* Premium members only.
The historical data trend for Cell Impact's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ICL vs CRS, ATI, MLI: Enterprise Value Comparison
For the Metal Fabrication subindustry, Cell Impact's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cell Impact Enterprise Value vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Cell Impact's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Cell Impact's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Cell Impact's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cell Impact (FRA:ICL) has a Enterprise Value of €5.45 Mil as of Jun. 30, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Cell Impact and its competitors.
Is Cell Impact's Enterprise Value too high?
Cell Impact's current Enterprise Value is €5.45 Mil. Overall, Cell Impact has a GF Score™ of 25/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cell Impact's Enterprise Value compare to CRS and ATI?
Cell Impact's Enterprise Value of €5.45 Mil can be compared against companies in the Industrial Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for an Industrial Products company?
A good Enterprise Value depends on the Industrial Products industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Cell Impact and its competitors. Cell Impact's current Enterprise Value is €5.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Impact stock overvalued right now?
Based on GuruFocus' analysis, Cell Impact (FRA:ICL) is currently considered Fairly Valued. The stock's GF Value™ is €0.01, compared to a current price of €0.01 — trading right at its estimated fair value. The current Enterprise Value is €5.45 Mil. Cell Impact's overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Cell Impact (FRA:ICL), the current Enterprise Value is €5.45 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cell Impact (FRA:ICL) Overvalued in 2026?
Based on GuruFocus' analysis, Cell Impact stock appears to be undervalued.
The current stock price of €0.01 is trading 0% below its estimated GF Value™ of €0.01.
GuruFocus considers Cell Impact to be Fairly Valued.
Key valuation signals for FRA:ICL:
Enterprise Value: €5.45 Mil
GF Value™: €0.01 vs. price of €0.01 (0% below fair value)
No single metric tells the full story. See the FRA:ICL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cell Impact develops and manufactures flow plates for fuel cells and electrolyzers using materials such as graphite, stainless steel, and titanium. The company has developed and patented a high-velocity forming method, known as Cell Impact Forming, which enables the production of flow plates with advanced designs. Geographically, it operates in Sweden, Asia, the U.S., and Other Europe. It generates the majority of its revenue from Sweden.
25GF Score
Get the complete analysis for FRA:ICL
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ICL has been successfully added to your 
